Details for New Drug Application (NDA): 060716
✉ Email this page to a colleague
NDA 060716 describes POLYMYXIN B SULFATE, which is a drug marketed by Adrastea Pharma, Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma, Rising, Xellia Pharms Aps, and Paddock Llc, and is included in eight NDAs. It is available from seven suppliers. Additional details are available on the POLYMYXIN B SULFATE profile page.
The generic ingredient in POLYMYXIN B SULFATE is polymyxin b sulfate. There are twelve drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the polymyxin b sulfate profile page.
The generic ingredient in POLYMYXIN B SULFATE is polymyxin b sulfate. There are twelve drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the polymyxin b sulfate profile page.
Summary for 060716
| Tradename: | POLYMYXIN B SULFATE |
| Applicant: | Hikma |
| Ingredient: | polymyxin b sulfate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 060716
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| POLYMYXIN B SULFATE | polymyxin b sulfate | INJECTABLE;INJECTION | 060716 | ANDA | Hikma Pharmaceuticals USA Inc. | 0143-9941 | 0143-9941-10 | 10 VIAL in 1 CARTON (0143-9941-10) / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL (0143-9941-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | EQ 500,000 UNITS BASE/VIAL | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
